Steady-State Pharmacokinetics of Twice-Daily Dosing of Saquinavir Plus Ritonavir in HIV-1–Infected Individuals
Authors:
- Agnes I. VeldkampAVAgnes I. Veldkamp
- Rolf P. G. van HeeswijkRHRolf P. G. van Heeswijk
- Jan W. MulderJMJan W. Mulder
- Pieter L. MeenhorstPMPieter L. Meenhorst
- Gerrit SchreijGSGerrit Schreij
- Siebe van der GeestSGSiebe van der Geest
- Joep M. A. LangeJLJoep M. A. Lange
- Jos H. BeijnenJBJos H. Beijnen
- Richard M. W. HoetelmansRHRichard M. W. Hoetelmans
- 1 August 2001
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 27 (4) , 344-349
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudineAIDS, 2000
- The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoringAIDS, 1999
- Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?AIDS, 1999
- Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patientsAIDS, 1999
- Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimensAIDS, 1999
- Outcome and Predictors of Failure of Highly Active Antiretroviral Therapy: One‐Year Follow‐Up of a Cohort of Human Immunodeficiency Virus Type 1–Infected PersonsThe Journal of Infectious Diseases, 1999
- Ritonavir and saquinavir combination therapy for the treatment of HIV infectionAIDS, 1999
- Drug Interactions of HIV Protease InhibitorsDrug Safety, 1999
- Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir*Clinical Pharmacology & Therapeutics, 1998
- Saquinavir Soft-Gel Capsule FormulationDrugs, 1998